Advertisement
UK markets close in 7 hours 22 minutes

  • FTSE 100

    8,061.44
    +37.57 (+0.47%)
     

  • FTSE 250

    19,667.12
    +67.73 (+0.35%)
     

  • AIM

    751.82
    +2.64 (+0.35%)
     

  • GBP/EUR

    1.1575
    -0.0014 (-0.12%)
     

  • GBP/USD

    1.2358
    +0.0008 (+0.06%)
     

  • Bitcoin GBP

    53,542.67
    +59.94 (+0.11%)
     

  • CMC Crypto 200

    1,394.50
    -20.26 (-1.43%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    82.54
    +0.64 (+0.78%)
     

  • GOLD FUTURES

    2,324.20
    -22.20 (-0.95%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,824.52
    +312.83 (+1.89%)
     

  • DAX

    17,985.80
    +125.00 (+0.70%)
     

  • CAC 40

    8,058.08
    +17.72 (+0.22%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden

Reuters - UK Focus

MUMBAI, Sept 1 (Reuters) - India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc (Other OTC: GLAXF - news) 's Advair, a move that will further dent sales of the British firm's top-selling product.

Cipla's drug will be marketed under the name Serrofloin in Germany and Salmeterol/Fluticasone Cipla in Sweden, the Mumbai-based company said in a statement on Monday.

In December, Denmark became the first European country to approve for sale a generic version of GlaxoSmithKline's $8 billion-a-year Advair, and analysts have been expecting more such approvals.

Making copies of inhaled drugs such as Advair is a challenge because of the complexity of making a device that effectively delivers the medicine directly into the lungs.

(Reporting by Zeba Siddiqui in Mumbai; Editing by Prateek Chatterjee)